12.11.2018 • NewsBoehringer IngelheimDede Willams

Boehringer Expands Biopharmaceuticals in US

Boehringer Expands Biopharmaceuticals in US (c) Boehringer
Boehringer Expands Biopharmaceuticals in US (c) Boehringer

Germany’s Boehringer Ingelheim has opened a new US biopharmaceutical manufacturing facility at Fremont, California, expanding its worldwide bioreactor capacity to 290,000 liters. The US plant, which cost €200 million to build, employs 300 people.

With the start-up, the company said it is now “well-positioned” to manufacture new biological products from its own research pipeline as well as provide contract manufacturing for other pharmaceutical and biopharmaceutical companies.

“The completion of our expansion in Fremont marks another milestone in our biopharmaceutical growth strategy,” said Uwe Bücheler, head of the Boehringer Biopharmaceuticals business unit. “Our locations in the United States, Germany, Austria, and China are contributing to the development of innovative biopharmaceuticals for patients worldwide.”

Biopharmaceuticals make up around 40% of the active ingredient candidates from the German company’s research pipeline. Its biotech contract manufacturing arm, which operates on the BioXcellence platform, saw double-digit growth last year and currently formulates 31 biopharmaceutical medicines for customers worldwide.

According to Boehringer, it can provide “the entire production technology chain from DNA to fill and finish” through its network in Biberach, Germany; Vienna, Austria; Fremont and Shanghai, China.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.